Bile acid alterations associated with indolent course of inflammatory bowel disease

References

• Torres J, Mehandru S, Colombel JF, et al. Crohn’s disease. Lancet. 2017;389(10080):1741–1755.
   PubMed Web of Science ®Google Scholar
• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770.
   PubMed Web of Science ®Google Scholar
• Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769–2778.
   PubMed Web of Science ®Google Scholar
• Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. JAMA Pediatr. 2015;169(11):1053–1060.
   PubMed Web of Science ®Google Scholar
• Wintjens D, Bergey F, Saccenti E, et al. Disease activity patterns of Crohn’s disease in the first ten years after diagnosis in the population-based IBD South Limburg cohort. J Crohns Colitis. 2021;15(3):391–400.
   PubMed Web of Science ®Google Scholar
• Fumery M, Singh S, Dulai PS, et al. Natural history of adult ulcerative colitis in population-based cohorts: a systematic review. Clin Gastroenterol Hepatol. 2018;16(3):343–356 e3.
   PubMed Web of Science ®Google Scholar
• Ashton JJ, Mossotto E, Ennis S, et al. Personalising medicine in inflammatory bowel disease-current and future perspectives. Transl Pediatr. 2019;8(1):56–69.
   PubMed Web of Science ®Google Scholar
• Verstockt B, Parkes M, Lee J. How do We predict a patient’s disease course and whether they will respond to specific treatments? Gastroenterology. 2022;162(5):1383–1395.
   PubMed Web of Science ®Google Scholar
• Schmidt C, Bokemeyer B, Lugering A, et al. Clinical predictors for a complicated course of disease in an inception cohort of patients with ulcerative colitis: results from the prospective, observational EPICOL study. Int J Colorectal Dis. 2022;37(2):485–493.
   PubMed Web of Science ®Google Scholar
• Halligan S, Boone D, Archer L, et al. Prognostic biomarkers to identify patients likely to develop severe Crohn’s disease: a systematic review. Health Technol Assess. 2021;25(45):1–66.
   Web of Science ®Google Scholar
• Kugathasan S, Denson LA, Walters TD, et al. Prediction of complicated disease course for children newly diagnosed with Crohn’s disease: a multicentre inception cohort study. Lancet. 2017;389(10080):1710–1718.
   PubMed Web of Science ®Google Scholar
• Blonski W, Buchner AM, Lichtenstein GR. Clinical predictors of aggressive/disabling disease: ulcerative colitis and Crohn disease. Gastroenterol Clin North Am. 2012;41(2):443–462.
   PubMed Web of Science ®Google Scholar
• Yarur AJ, Strobel SG, Deshpande AR, et al. Predictors of aggressive inflammatory bowel disease. Gastroenterol Hepatol. 2011;7(10):652–659.
   Google Scholar
• Yanai H, Goren I, Godny L, et al. Early indolent course of Crohn’s disease in newly diagnosed patients is not rare and possibly predictable. Clin Gastroenterol Hepatol. 2021;19(8):1564–1572 e5.
   PubMedGoogle Scholar
• Li N, Shukai Z, Caiguang L, et al. Development and validation of a nomogram to predict indolent course in patients with ulcerative colitis: a single-center retrospective study. Gastroenterol Rep. 2022;10:goac029.
   Google Scholar
• Wishart DS. Metabolomics for investigating physiological and pathophysiological processes. Physiol Rev. 2019;99(4):1819–1875.
   PubMed Web of Science ®Google Scholar
• Iyer N, Corr SC. Gut microbial metabolite-mediated regulation of the intestinal barrier in the pathogenesis of inflammatory bowel disease. Nutrients. 2021;13(12):4259.
   PubMed Web of Science ®Google Scholar
• Chen RR, Zheng JQ, Li L, et al. Metabolomics facilitate the personalized management in inflammatory bowel disease. Therap Adv Gastroenterol. 2021;14:17562848211064489.
   Web of Science ®Google Scholar
• Bjerrum JT, Wang YL, Seidelin JB, et al. IBD metabonomics predicts phenotype, disease course, and treatment response. EBioMedicine. 2021;71:103551.
   PubMed Web of Science ®Google Scholar
• Storr M, Vogel HJ, Schicho R. Metabolomics: is it useful for inflammatory bowel diseases? Curr Opin Gastroenterol. 2013;29(4):378–383.
   PubMed Web of Science ®Google Scholar
• Thomas JP, Modos D, Rushbrook SM, et al. The emerging role of bile acids in the pathogenesis of inflammatory bowel disease. Front Immunol. 2022;13:829525.
   PubMed Web of Science ®Google Scholar
• Chen ML, Takeda K, Sundrud MS. Emerging roles of bile acids in mucosal immunity and inflammation. Mucosal Immunol. 2019;12(4):851–861.
   PubMed Web of Science ®Google Scholar
• Lee JWJ, Plichta D, Hogstrom L, et al. Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. Cell Host Microbe. 2021;29(8):1294–1304 e4.
   PubMed Web of Science ®Google Scholar
• Ding NS, McDonald JAK, Perdones-Montero A, et al. Metabonomics and the gut microbiome associated with primary response to anti-TNF therapy in Crohn’s disease. J Crohns Colitis. 2020;14(8):1090–1102.
   PubMed Web of Science ®Google Scholar
• Connors J, Dunn KA, Allott J, et al. The relationship between fecal bile acids and microbiome community structure in pediatric Crohn’s disease. Isme J. 2020;14(3):702–713.
   PubMed Web of Science ®Google Scholar
• Paramsothy S, Nielsen S, Kamm MA, et al. Specific bacteria and metabolites associated with response to fecal microbiota transplantation in patients with ulcerative colitis. Gastroenterology. 2019;156(5):1440–1454 e2.
   PubMed Web of Science ®Google Scholar
• Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749–753.
   PubMed Web of Science ®Google Scholar
• Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60(4):505–512.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132(2):763–786.
   PubMed Web of Science ®Google Scholar
• Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn’s disease activity index. National cooperative Crohn’s disease study. Gastroenterology. 1976;70(3):439–444.
   PubMed Web of Science ®Google Scholar
• Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 2006;47(2):241–259.
   PubMed Web of Science ®Google Scholar
• Li N, Zhan SK, Tian ZY, et al. Alterations in bile acid metabolism associated with inflammatory bowel disease. Inflamm Bowel Dis. 2021;27(9):1525–1540.
   PubMed Web of Science ®Google Scholar
• Greve JW, Gouma DJ, Buurman WA. Bile acids inhibit endotoxin-induced release of tumor necrosis factor by monocytes: an in vitro study. Hepatology. 1989;10(4):454–458.
   PubMed Web of Science ®Google Scholar
• Yoneno K, Hisamatsu T, Shimamura K, et al. TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn’s disease. Immunology. 2013;139(1):19–29.
   PubMed Web of Science ®Google Scholar
• Duboc H, Rajca S, Rainteau D, et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2013;62(4):531–539.
   PubMed Web of Science ®Google Scholar
• Sorrentino G, Perino A, Yildiz E, et al. Bile acids signal via TGR5 to activate intestinal stem cells and epithelial regeneration. Gastroenterology. 2020;159(3):956–968 e8.
   PubMed Web of Science ®Google Scholar
• Sinha SR, Haileselassie Y, Nguyen LP, et al. Dysbiosis-induced secondary bile acid deficiency promotes intestinal inflammation. Cell Host Microbe. 2020;27(4):659–670 e5.
   PubMed Web of Science ®Google Scholar
• Cipriani S, Mencarelli A, Chini MG, et al. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS One. 2011;6(10):e25637.
   PubMed Web of Science ®Google Scholar
• Biagioli M, Carino A, Cipriani S, et al. The bile acid receptor GPBAR1 regulates the M1/M2 phenotype of intestinal macrophages and activation of GPBAR1 rescues mice from murine colitis. J Immunol. 2017;199(2):718–733.
   PubMed Web of Science ®Google Scholar
• Perino A, Schoonjans K. TGR5 and immunometabolism: insights from physiology and pharmacology. Trends Pharmacol Sci. 2015;36(12):847–857.
   PubMed Web of Science ®Google Scholar
• Yang ZH, Liu F, Zhu XR, et al. Altered profiles of fecal bile acids correlate with gut microbiota and inflammatory responses in patients with ulcerative colitis. World J Gastroenterol. 2021;27(24):3609–3629.
   PubMed Web of Science ®Google Scholar
• Das P, Marcišauskas S, Ji B, et al. Metagenomic analysis of bile salt biotransformation in the human gut microbiome. BMC Genomics. 2019;20(1):517.
   PubMed Web of Science ®Google Scholar
• Guo S, Peng Y, Lou Y, et al. Downregulation of the farnesoid X receptor promotes colorectal tumorigenesis by facilitating enterotoxigenic Bacteroides fragilis colonization. Pharmacol Res. 2022;177:106101.
   PubMed Web of Science ®Google Scholar
• Mühlbauer M, Allard B, Bosserhoff AK, et al. Differential effects of deoxycholic acid and taurodeoxycholic acid on NF-kappa B signal transduction and IL-8 gene expression in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2004;286(6):G1000–G1008.
   PubMed Web of Science ®Google Scholar
• Strauch ED, Bass BL, Rao JN, et al. NF-kappaB regulates intestinal epithelial cell and bile salt-induced migration after injury. Ann Surg. 2003;237(4):494–501.
   PubMed Web of Science ®Google Scholar
• Wong WY, Chan BD, Sham TT, et al. Lactobacillus casei strain shirota ameliorates dextran sulfate Sodium-Induced colitis in mice by increasing taurine-conjugated bile acids and inhibiting NF-κB signaling via stabilization of IκBα. Front Nutr. 2022;9:816836.
   PubMed Web of Science ®Google Scholar
• Quante M, Iske J, Uehara H, et al. Taurodeoxycholic acid and valine reverse obesity-associated augmented alloimmune responses and prolong allograft survival. Am J Transplant. 2022;22(2):402–413.
   PubMed Web of Science ®Google Scholar
• Zahiri HR, Perrone EE, Strauch ED. Bile salt supplementation acts via the farnesoid X receptor to alleviate lipopolysaccharide-induced intestinal injury. Surgery. 2011;150(3):480–489.
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Distrutti E, Carino A, et al. Bile acids and their receptors in metabolic disorders. Prog Lipid Res. 2021;82:101094.
   PubMed Web of Science ®Google Scholar
• Inagaki T, Moschetta A, Lee YK, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A. 2006;103(10):3920–3925.
   PubMed Web of Science ®Google Scholar
• Gadaleta RM, van Erpecum KJ, Oldenburg B, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 2011;60(4):463–472.
   PubMed Web of Science ®Google Scholar
• Huo X, Li D, Wu F, et al. Cultivated human intestinal fungus Candida metapsilosis M2006B attenuates colitis by secreting acyclic sesquiterpenoids as FXR agonists. Gut. 2022;71(11):2205–2217.
   PubMed Web of Science ®Google Scholar
• Paik D, Yao LN, Zhang YC, et al. Human gut bacteria produce TH 17-Modulating bile acid metabolites. BioRxiv. 2021.
   Google Scholar
• Song X, Sun X, Oh SF, et al. Microbial bile acid metabolites modulate gut RORγ+ regulatory T cell homeostasis. Nature. 2020;577(7790):410–415.
   PubMed Web of Science ®Google Scholar
• Alnouti Y. Bile acid sulfation: a pathway of bile acid elimination and detoxification. Toxicol Sci. 2009;108(2):225–246.
   PubMed Web of Science ®Google Scholar
• Britton GJ, Contijoch EJ, Mogno I, et al. Microbiotas from humans with inflammatory bowel disease alter the balance of gut Th17 and RORγt + regulatory T cells and exacerbate colitis in mice. Immunity. 2019;50(1):212–224.e4.
   PubMed Web of Science ®Google Scholar
• Alexander M, Ang QY, Nayak RR, et al. Human gut bacterial metabolism drives Th17 activation and colitis. Cell Host Microbe. 2022;30(1):17–30.e9.
   PubMed Web of Science ®Google Scholar
• Igaki K, Nakamura Y, Tanaka M, et al. Pharmacological effects of TAK-828F: an orally available RORγt inverse agonist, in mouse colitis model and human blood cells of inflammatory bowel disease. Inflamm Res. 2019;68(6):493–509.
   PubMed Web of Science ®Google Scholar
• Funk RS, Becker ML. Metabolomic profiling identifies exogenous and microbiota-derived metabolites as markers of methotrexate efficacy in juvenile idiopathic arthritis. Front Pharmacol. 2021;12:768599.
   PubMed Web of Science ®Google Scholar
• Heinken A, Ravcheev DA, Baldini F, et al. Systematic assessment of secondary bile acid metabolism in gut microbes reveals distinct metabolic capabilities in inflammatory bowel disease. Microbiome. 2019;7(1):75.
   PubMed Web of Science ®Google Scholar
• Murakami M, Iwamoto J, Honda A, et al. Detection of gut dysbiosis due to reduced clostridium subcluster XIVa using the fecal or serum bile acid profile. Inflamm Bowel Dis. 2018;24(5):1035–1044.
   PubMed Web of Science ®Google Scholar